GlassScriptPhysician profile
Allison S Riley
NPI 1427729664
$2,027.61
in general payments reported to CMS, 2019-2025
32 companies · $864 in 2025
The $864 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $124 · 2023: $563 · 2024: $476 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.56 | 2023-2025 | |
| Ardelyx, INC. | $292.19 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $147.87 | 2023-2025 | Mounjaro, Trulicity, Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.50 | 2023-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $102.50 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $83.62 | 2023 | Recorlev, Gvoke Hypopen |
| Janssen Biotech, INC. | $82.33 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Boston Scientific Corporation | $71.88 | 2022-2024 | Wavewriter Alpha Prime 16, Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $68.62 | 2023-2024 | Entyvio |
| Sanofi-Aventis U.S. LLC | $55.33 | 2023 | |
| Redhill Biopharma INC. | $52.25 | 2023 | Talicia |
| Phathom Pharmaceuticals, INC. | $47.85 | 2024-2025 | Voquezna |
| Amneal Pharmaceuticals LLC | $46.33 | 2023 | Unithroid |
| Renalytix Ai, INC. | $46.16 | 2022 | |
| Pfizer INC. | $45.69 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $37.85 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $35.79 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $35.43 | 2024 | |
| Ibsa Pharma INC. | $32.06 | 2022 | |
| Aimmune Therapeutics, INC. | $31.03 | 2024-2025 | Zenpep |
| Genzyme Corporation | $22.48 | 2025 | |
| Daiichi Sankyo INC. | $21.79 | 2025 | Injectafer |
| Braintree Laboratories, INC. | $20.32 | 2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $19.25 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.07 | 2023 | Jardiance, Synjardy |
| Celgene Corporation | $18.58 | 2024 | Zeposia |
| Medtronic, INC. | $17.90 | 2022 | |
| Esperion Therapeutics, INC. | $16.67 | 2023 | Nexletol |
| Enterra Medical, INC. | $15.42 | 2023 | |
| Amgen INC. | $14.91 | 2023 | Prolia, Evenity |
| Intercept Pharmaceuticals, INC. | $13.38 | 2023 | Ocaliva |
| Cequr Corporation | $12.00 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.